Deals: Page
-
Carol Highsmith. (2005). "The Apex Building" [Photo]. Retrieved from Wikimedia Commons.
As Merck closes in on Seagen, the FTC nears a key test on pharma deals
An acquisition reportedly worth $40 billion or more and potentially signed within weeks could draw notable scrutiny from regulators and force the companies to divest certain drug programs.
By Jonathan Gardner , Ben Fidler • July 7, 2022 -
Getty Images
Two cancer biotechs merge, raise cash as sector-wide downturn continues
Syros Pharmaceuticals and Tyme Technologies, shares of which trade near all-time lows, will combine and raise about $130 million in the latest example of how the industry’s slump is affecting publicly traded biotechs.
By Delilah Alvarado • July 5, 2022 -
Courtesy of CureVac
CureVac sues rival COVID-19 vaccine maker BioNTech for patent infringement
The biotech, whose own efforts to develop a COVID-19 vaccine have faltered, claims its inventions were crucial to the development of BioNTech’s top-selling coronavirus shot.
By Jonathan Gardner • July 5, 2022 -
Christopher Furlong via Getty Images
With $100M AstraZeneca deal, a biotech and its investors engineer another buyout
An entity originally known as Teneobio has now been the focus of three acquisition deals with large pharmaceutical companies since 2021, capitalizing on the industry’s growing interest in dual-acting antibody drugs.
By Ben Fidler • July 5, 2022 -
Brian Tucker / BioPharma Dive/BioPharma Dive
Blueprint secures access to more than $1B in funding through two new deals
Amid a historic market downturn, the precision drug company is raising money through royalty financings with Sixth Street and Royalty Pharma.
By Jacob Bell • June 30, 2022 -
Getty Images
Bayer, Amgen back ReCode's plan to broaden genetic medicine's reach
The two drugmakers joined a long list of investors, including Pfizer and Sanofi, that have been funding the startup’s plan to develop a new type of lipid nanoparticle technology.
By Delilah Alvarado • June 29, 2022 -
Elizabeth Regan/BioPharma Dive
Ipsen adds to cancer business with bargain buyout of Epizyme
Epizyme, which was once worth more than $2 billion, agreed to be bought for $247 million upfront. The biotech has continued to lose money despite winning FDA approval for a drug for rare cancers.
By Jonathan Gardner • June 27, 2022 -
Radius, maker of bone and cancer drugs, to be bought in take-private deal
Two investment firms, Gurnet Point Capital and Patient Square Capital, have agreed to pay as much as $890 million for Radius, which has come under pressure amid share price declines.
By Ben Fidler, Kristin Jensen • June 23, 2022 -
Courtesy of Galapagos
Galapagos, with latest deals, charts an unexpected journey to cell therapy
The Belgian drugmaker will spend more than $100 million to acquire two companies, CellPoint and AboundBio, in a move meant to “disrupt” CAR-T treatment.
By Jacob Bell • June 22, 2022 -
Getty Images
Boehringer extends cancer dealmaking with right to buy biotech partner
The German pharma company has secured an option to acquire Trutino Biosciences, two years after inking a research collaboration with the San Diego drug developer.
By Delilah Alvarado • June 16, 2022 -
Carol Highsmith. (2005). "The Apex Building" [Photo]. Retrieved from Wikimedia Commons.
Pharma under the microscope as FTC considers new ways to review acquisitions
At a two-day meeting, experts argued drug divestitures may not be enough to prevent market concentration. Economists and regulators also appeared worried by the effect of buyouts on innovation.
By Jonathan Gardner • June 16, 2022 -
Getty Images
Resilience, a well-funded manufacturing startup, joins with the Parker Institute to make cancer drugs
The unusual biotech, which just raised $625 million earlier this week, will work with the immunotherapy center under a five-year agreement to create and spin off new companies.
By Kristin Jensen • June 9, 2022 -
Yumanity's days as an independent biotech come to a close
After recently announcing plans to eliminate more than half its staff, the biotech now intends to sell its research programs to Janssen and enter a reverse merger with the private company Kineta.
By Jacob Bell • June 6, 2022 -
Permission granted by Bristol-Myers Squibb
Bristol Myers bets $4B on Turning Point and its targeted cancer drugs
While priced at a significant premium, the deal values Turning Point well below its peak valuation last year, a potential sign biotechs might be adjusting their expectations amid the sector's downturn.
By Jonathan Gardner • Updated June 3, 2022 -
Leon Neal via Getty Images
GSK wagers $2.1B on Affinivax and its next-generation pneumonia vaccine
The deal is the second acquisition for GSK since April and gives the company access to an experimental shot that’s meant to surpass new products from Pfizer and Merck & Co.
By Ben Fidler • May 31, 2022 -
National Institute of Allergy and Infectious Diseases. (2020). "Novel Coronavirus SARS-CoV-2" [Micrograph]. Retrieved from Flickr.
NIH licenses COVID-19 technologies to WHO-backed program
The agreement, which covers three experimental vaccines as well as several key patents, will be royalty free for products sold in 49 low-income countries.
By Jonathan Gardner • May 13, 2022 -
Getty Images
Taiho, chasing larger rivals, buys back rights to Cullinan cancer drug
The deal hands $275 million upfront to Cullinan, whose medicine is being developed for a genetic driver of lung tumors that's become a top target for drugmakers.
By Kristin Jensen • May 12, 2022 -
Dan Kitwood via Getty Images
Pfizer to acquire Biohaven in $11.6B bet on biotech's migraine drugs
The deal, which hands Pfizer full rights to the biotech's fast-selling Nurtec ODT, could provide a much needed spark for the sector after months of stock market declines.
By Ben Fidler , Jacob Bell • Updated May 10, 2022 -
Permission granted by Biogen
Biogen, having scrapped Aduhelm, tries to convince investors of turnaround plan
Though executives claimed that inking deals and derisking research programs are priorities, analysts questioned whether any meaningful strategic changes will occur in the near term.
By Jacob Bell • May 4, 2022 -
National Institutes of Allergy and Infectious Diseases. (2016). "Human natural killer cell" [Micrograph]. Retrieved from Flickr.
A cancer biotech attracts another deep-pocketed partner in Gilead
Following rivals like Bristol Myers Squibb and Merck, Gilead has linked up with Dragonfly Therapeutics to develop new immunotherapies based on "natural killer cell engagers."
By Jacob Bell • May 2, 2022 -
A promising cancer drug leads Regeneron to reconsider its aversion to M&A
Regeneron has agreed to purchase Checkmate Pharmaceuticals for $250 million, the first acquisition of a publicly traded company in the biotech's nearly 35-year history.
By Jacob Bell • April 19, 2022 -
Brian Tucker/BioPharma Dive
Halozyme, doubling down on a licensing strategy, buys a drug delivery biotech for nearly $1B
Antares Pharma's auto-injector technology is of particular interest to Halozyme, which believes that the various markets to which it could be applied represent billions of dollars in potential sales.
By Jacob Bell • April 13, 2022 -
Warren Little via Getty Images
GSK acquires Sierra Oncology, betting $2B on a bone cancer drug with a long history
The British pharma is buying into the potential of a medicine meant to treat the anemia often associated with myelofibrosis, a complication that isn't adequately addressed by current therapies.
By Ben Fidler , Ned Pagliarulo • April 13, 2022 -
Maddie Meyer via Getty Images
Pfizer, Moderna name new finance chiefs amid surging revenue
Pfizer is bringing in former Lowe's and CVS Health executive David Denton, while Moderna hired Jorge Gomez, previously CFO at Cardinal Health. Both take the reins as their new companies face strategic questions.
By Jonathan Gardner • April 11, 2022 -
Dan Kitwood via Getty Images
Pfizer buys a private biotech and its RSV drug research
The pharma company will add experimental RSV treatments to its pipeline through the deal, which is worth up to $525 million.
By Kristin Jensen • April 7, 2022
Previous
